Genmab A/S (FRA:GE9)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of EUR 15.29 billion. The enterprise value is 18.45 billion.

Market Cap	15.29B
Enterprise Value	18.45B

Important Dates

The last earnings date was Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.62M
Shares Outstanding	n/a
Shares Change (YoY)	-3.04%
Shares Change (QoQ)	+1.68%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.90M

Valuation Ratios

The trailing PE ratio is 18.64 and the forward PE ratio is 21.44.

PE Ratio	18.64
Forward PE	21.44
PS Ratio	4.83
PB Ratio	3.07
P/TBV Ratio	n/a
P/FCF Ratio	15.62
P/OCF Ratio	15.13
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.58, with an EV/FCF ratio of 18.85.

EV / Earnings	22.49
EV / Sales	5.82
EV / EBITDA	16.58
EV / EBIT	17.33
EV / FCF	18.85

Financial Position

The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.93.

Current Ratio	2.02
Quick Ratio	2.01
Debt / Equity	0.93
Debt / EBITDA	4.15
Debt / FCF	4.72
Interest Coverage	20.49

Financial Efficiency

Return on equity (ROE) is 17.53% and return on invested capital (ROIC) is 16.61%.

Return on Equity (ROE)	17.53%
Return on Assets (ROA)	8.10%
Return on Invested Capital (ROIC)	16.61%
Return on Capital Employed (ROCE)	10.92%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.07M
Profits Per Employee	275,879
Employee Count	2,681
Asset Turnover	0.39
Inventory Turnover	17.63

Taxes

In the past 12 months, Genmab has paid 205.26 million in taxes.

Income Tax	205.26M
Effective Tax Rate	20.02%

Stock Price Statistics

The stock price has increased by +14.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+14.78%
50-Day Moving Average	267.75
200-Day Moving Average	219.21
Relative Strength Index (RSI)	38.54
Average Volume (20 Days)	4

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of EUR 3.17 billion and earned 820.19 million in profits. Earnings per share was 13.09.

Revenue	3.17B
Gross Profit	2.97B
Operating Income	1.06B
Pretax Income	1.03B
Net Income	820.19M
EBITDA	1.10B
EBIT	1.06B
Earnings Per Share (EPS)	13.09

Balance Sheet

The company has 1.46 billion in cash and 4.62 billion in debt, with a net cash position of -3.16 billion.

Cash & Cash Equivalents	1.46B
Total Debt	4.62B
Net Cash	-3.16B
Net Cash Per Share	n/a
Equity (Book Value)	4.98B
Book Value Per Share	80.82
Working Capital	1.24B

Cash Flow

In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -31.51 million, giving a free cash flow of 978.60 million.

Operating Cash Flow	1.01B
Capital Expenditures	-31.51M
Free Cash Flow	978.60M
FCF Per Share	n/a

Margins

Gross margin is 93.60%, with operating and profit margins of 33.60% and 25.89%.

Gross Margin	93.60%
Operating Margin	33.60%
Pretax Margin	32.37%
Profit Margin	25.89%
EBITDA Margin	34.68%
EBIT Margin	33.60%
FCF Margin	30.89%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.04%
Shareholder Yield	3.04%
Earnings Yield	5.37%
FCF Yield	6.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 2.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.48
Piotroski F-Score	4